USA flag logo/image

An Official Website of the United States Government

Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80313
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA119565
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
AMBERGEN, INC
AMBERGEN, INC 313 PLEASANT ST WATERTOWN, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
Agency: HHS
Contract: 2R44CA119565-05
Award Amount: $2,998,830.00
 

Abstract:

DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer deaths in the U.S and Western world. Despite  increased screening and advances in treatment, the mortality rate (~50,000/year) and high national health-care  burden for CRC is likely to remain high unless more effective methods are developed to predict recurrence and  response to chemo-radiation therapy. For example, the five-year survival rate of CRC is 90% for the over 70%  of patients who do not recur (even without therapy). However, this rate for non-local metastasized CRC  (mCRC) drops to only 10%. CRC treatment and the patient outcome could be significantly improved if it could  be focused on only those patients who need and are most likely to benefit from the therapy. For this reason  the NCI has made as a critical goal the  Discovery of new indicators of prognosis and the likelihood of  response to chemotherapy and radiation  (Recommendations of the NCI Colorectal Cancer Progress Review  Group (PRG), 2000).  As a result of the Phase II, AmberGen has developed a promising CRC tumor assay based on multi-gene  expression profiling, termed the Praxis-CRCTM. This assay is designed to accurately predict the likelihood of  CRC recurrence and response to therapies used to treat post-surgical CRC patients including major  chemotherapies and external beam radiotherapy. The initial assay developed and evaluated in Phase II  requires only 4 genes to predict recurrence (mCRC) with over 95% accuracy and 4 genes to predict response  to 5-fluorouracil (5-FU) therapy with over 91% accuracy as described in the proposal. This compares favorably  to commercial assays developed for breast cancer such as OncoDxTM (Genomic Health) which utilize a panel  of over 25 genes with much less accuracy. Novel steps in the development of the Praxis-CRCTM signature  include: i) Acquisition of high-quality fresh-frozen CRC tumor samples with known clinical outcome data going  back 5 years, ii) Measurement and analysis of low-noise gene expression microarray data, iii) Generation of  priority gene list by Meta-Analysis, iv) Validation of the priority gene list by RT-PCR on FFPE samples with  known outcome for over 5 years, v) Development of the final assay on an industry standard 384-well RTPCR  platform.  This Phase II Bridge project is aimed at accelerating the commercialization of Praxis-CRCTM. This will involve  further refinement and evaluation of signatures to predict outcome of common therapies such as folfox, folfiri  and external radiation using 300 well-documented clinical FFPE tumor samples. The project involves a  partnership between AmberGen and a global leader in biomedical assay products with over  1.7 billion in  revenue in 2008 and a total of 9,000 employees. As a result of the success of the Phase II project and the  opportunity to receive SBIR Phase II Bridge funding, this company will provide at least  6M in funds for the  additional costs of commercialization including a large-scale multi-institution validation study, FDA regulatory  approval and world-wide marketing of PRAXIS-CRCTM. The project also includes participation by the Ontario  Institute of Cancer Research (OICR), Dana Farber Cancer Institute and the UCSD Morris Cancer Center,  major sources of high quality CRC tumor samples, Ananomouse, Corp, (subcontractor) the developer of  PRAXISTM, advanced software for the collection and analysis of microarray gene expression data, and  WaferGen Biosystems, Inc., developer of SmartChip  Real-Time PCR System which will be used for  improved initial biomarker discovery.        PUBLIC HEALTH RELEVANCE: There exists an urgent need for an accurate recurrence and response to treatment prognostic assay for  colorectal cancer (CRC), the second leading cause of cancer-related death in the U.S. AmberGen seeks  funds to provide critical support for accelerated commercialization of PRAXIS-CRCTM, a gene expression-based  CRC tumor recurrence and response assay developed during Phase II. This assay will significantly  impact the treatment, quality of life and reduce the high health-care costs associated with CRC.

Principal Investigator:

Christopher Sears
6179239969
CSEARS@AMBERGEN.COM

Business Contact:

Shella Batelman
6179239990
shella@ambergen.com
Small Business Information at Submission:

AMBERGEN, INC
AMBERGEN, INC 313 PLEASANT ST WATERTOWN, MA 02472

EIN/Tax ID: 043228005
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No